Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRAÂ® Arbitration Case
yahoo.com
news
2022-10-16 20:48:00

$16.5 million to recover past royalties and interest

Cessation of double-digit royalty/supply payments

PEARL RIVER, N.Y., October 16, 2022--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that a three-judge arbitration panel has issued a final decision in a dispute with Alkermes PLC (Nasdaq: ALKS) regarding licensing royalties relating to AMPYRA (dalfampridine). Acorda was awarded $15 million plus prejudgment interest of $1.5 million from Alkermes. In addition, as a result of the panel's ruling, Acorda will no longer have to pay Alkermes any royalties on net sales for license and supply of AMPYRA, and Acorda is now free to use alternative sources for supply of AMPYRA, which the Company has already secured.
